A new biologic could change how we treat a stubborn swallowing disorder. The phase 3 CROSSING trial found that tezepelumab — already approved for asthma — dramatically improved histologic remission and dysphagia symptoms in eosinophilic esophagitis (EoE) patients compared to placebo, with benefits holding strong through 52 weeks. The drug was also well tolerated, with side effects comparable to placebo.
A new biologic could shake up treatment for eosinophilic esophagitis (EoE), a chronic inflammatory condition that causes painful swallowing and food impaction. The phase 3 CROSSING trial tested tezepelumab (Tezspire), a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP) — a key upstream driver of EoE's inflammatory cascade — in 365 patients aged 12–80 who had failed standard therapies. Results presented at the ACG Annual Scientific Meeting were striking: both doses far outperformed placebo on every major measure, and the benefits held through a full year.
Experts called the findings "highly encouraging," particularly because symptom improvement tracked alongside histologic and endoscopic improvements — something not always seen with other biologics. The once-monthly dosing schedule could also be a practical advantage over daily pills or weekly injections currently used in EoE management.
By the Numbers:
Why it matters: EoE remains a significant unmet need, with many patients failing current first-line treatments. Tezepelumab's consistent improvements across histologic, endoscopic, and symptom outcomes — plus its once-monthly convenience — could make it a valuable new option, while also deepening our understanding of EoE as a disease of epithelial-immune interaction, not just eosinophil overload.
